Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression

Date received: 8 April 2020; accepted: 23 April 2020

Italy has been one of the first European countries to face the spread of Coronavirus Disease-2019 (COVID-19). The affected patients have increased in number inexorably worldwide, reaching a pandemic dimension within a few weeks. The outbreak of COVID-19 represents a challenge for neurologists treating multiple sclerosis (MS). No data is available on whether patients with MS are at increased risk to develop severe forms of COVID-19. Since lymphopenia and immunosuppression are associated with worse outcomes, it is reasonable to hypothesise that MS-immunosuppressive treatments may lead to more severe infections, but there is no evidence to support this. We describe a case of mild uncomplicated COVID-19 occurring during intense immunosuppression a few days after alemtuzumab infusion.

On the same day that the first COVID-19 case was reported in Italy (21 February 2020), a 25-year-old girl with relapsing-remitting MS – working as a nurse in Milan – completed the second cycle of alemtuzumab treatment. She had started it 1 year before as first-line therapy due to highly active MS, and since then she had not experienced clinical relapses or new magnetic resonance imaging (MRI) activity. One week after the first Italian COVID-19 case, the patient was advised to stay home from work, due to the alarming spread of new affections. Nevertheless, 7 days later, she complained of dry cough, fatigue and fever up to 38.5°C. She was isolated at home and self-monitored blood oxygen saturation – which was always within normal range – and took acetaminophen. Symptoms gradually disappeared over 3 days, apart from cough that persisted for approximately 10 days. One week after symptom onset, she underwent nasopharyngeal swab for SARS-CoV2. On the same day, a blood test revealed a severe leukopenia with neutropenia and lymphopenia (leukocytes 1.19×10⁹/L, granulocytes-neutrophils 0.75×10⁹/L, lymphocytes 0.09×10⁹/L), but no elevation of inflammatory markers. Two weeks after the first swab, the second one was negative and the patient was asymptomatic (Supplementary material).

Alemtuzumab causes the depletion of CD52-expressing cells, leading to a transient alteration in lymphocyte numbers, trafficking and function after each course, and thus to an increased risk of infection, including both upper (very common; 10%) and lower respiratory tract infections (common; 1%–10%). The risk of COVID-19 in alemtuzumab-treated MS patients is unknown, but a higher risk is conceivable. For these reasons, Brownlee et al. recently recommended that alemtuzumab should not be initiated in MS patients who are about to start a treatment, and, for those already on treatment, to delay further courses, considering the risks and benefits. We described the case of a young woman who had COVID-19 few days after alemtuzumab infusion. Her blood counts were in line with the study by Li et al., reflecting an intense immunosuppression. Nonetheless, the patient had a mild infection and recovered within 2 weeks. On one hand, it should be noted that being a young woman without other medical conditions probably decreases the risk that COVID-19 results in severe illness. On the other hand, our report highlights the possibility that mild courses of COVID-19 may exist despite immunosuppression and that the spectrum of illness severity does not necessarily follow patient’s immune status. Further reports are needed to clarify the link between COVID-19 risk/severity/disease status and concomitant immunosuppressive medications.

Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: A.M.P., M.A.D.R. and E.S. declare no potential conflicts of interest. The author(s) received no financial support for the research, authorship and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship and/or publication of this article.

ORCID iDs
Tiziana Carandini https://orcid.org/0000-0002-0568-7580
Anna Margherita Pietroboni https://orcid.org/0000-0003-1538-1830
Filippo Martinelli Boneschi https://orcid.org/0000-0002-9955-1368
Supplemental material
Supplemental material for this article is available online.

References

Tiziana Carandini1, Anna Margherita Pietroboni1, Luca Sacchi1, Milena Alessandra De Riz1, Mattia Pozzato1, Andrea Arighi1, Giorgio Giulio Fumagalli1, Filippo Martinelli Boneschi1, Daniela Galimberti1, and Elio Scarpini1,2
1Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy
2University of Milan, Milan, Italy

Correspondence to:
T Carandini
Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Via Francesco Sforza 35, Milan 20122, Italy.
tizianacarandini@gmail.com